Biophan and New Scale Announce Newly Allowed Fundamental Patent on Tiny, Nano-Precise MRI-Compatible SQUIGGLE Motor.

ROCHESTER, N.Y. -- Proprietary SQUIGGLE(R) Motor Can Drive Wearable and Implantable Drug-Delivery Pumps, Other Applications

Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, and New Scale Technologies, Inc., a developer of miniature ceramic motors, have announced that the U.S. Patent and Trademark Office has allowed the fundamental patent for the revolutionary SQUIGGLE motor, a linear motor made of piezoelectric ceramics and other non-magnetic materials, which achieves nanometer precision. The Companies expect the patent will issue in the near future.

The SQUIGGLE motor's unique design enables advanced applications, such as the multi-billion-dollar market for implantable and wearable drug-delivery pumps. It is also safe and imageable for use in Magnetic Resonance Imaging (MRI) systems and other vacuum and ultra cold environments. Biophan holds the exclusive worldwide distribution rights to all medical applications using SQUIGGLE motors, produced by New Scale Technologies.

"This is great news for both Biophan and New Scale," said Michael Weiner, Biophan CEO. "The SQUIGGLE technology offers a number of unique features and capabilities that we believe will allow the development of significantly improved solutions for existing markets, as well as the development of applications for promising new markets in health care and medical technology."

The SQUIGGLE motor is constructed completely of non-magnetic ceramics and other advanced materials and is both totally safe and accurately imageable within Magnetic Resonance Imaging (MRI) systems. MRI compatibility enables the development of remote-controlled robotic surgical devices for MRI-guided procedures that require the highly precise positioning under real-time visual control, such as intra-cranial procedures to inject medicines into brain tumors.

The piezo electric ceramic SQUIGGLE motor occupies a unique and critical niche in the world of small motors for biomedical and other industry sectors. Using ultrasonic vibrations, it delivers significantly superior precision and electrical efficiency compared to older-generation electromagnetic motors, enabling longer battery life and reduced concerns with unwanted device heating. SQUIGGLE linear motors are five times more efficient and ten times more precise compared to electromagnetic motors.

The SQUIGGLE is constructed from only four parts--about 90% fewer than comparable electromagnetic medical device motors with gears. Because they require no gear reduction, a significant source of failure and malfunction is eliminated, increasing the SQUIGGLE's dependability. New Scale is producing a variety of SQUIGGLE models, ranging in size from 4 mm in diameter to 12 mm in diameter, with a variety of ranges of motion. The newest SQUIGGLE model, the SQ-306, is 50% smaller than the Company's previous models. A photo of the SQ-306 can be viewed at http://www.biophan.com/NewScale.jpg. It is 10 mm in length and 4 mm in diameter, and achieves precision levels in the nanometer-range.

The SQUIGGLE motor is also being developed for a number of important potential applications in sectors other than medicine, where its ultra-precise, silent and relatively powerful motorized movement is an advantage, such as automatic camera zoom lenses for cell phones and other active optical markets. In addition to its license of New Scale's SQUIGGLE for all medical applications, Biophan is also a minority equity owner in New Scale Technologies. New Scale currently sells a range of miniature motors and precision positioning systems that are powerful, and efficient, for emerging applications in nanotechnology, microelectronics, optics, lasers, biotechnology, medical devices, aerospace and defense, fluid control, and office/consumer products. (View "Biophan and New Scale Present Ceramic Motor for Medical Devices" video at http://www.biophan.com/ceramicvideo.php.)

About New Scale Technologies

New Scale Technologies, Inc. makes miniature motors and precision positioning systems that are cost effective, powerful, and efficient for emerging applications in nanotechnology, microelectronics, optics, lasers, biotechnology, medical devices, aerospace and defense, fluid control, and office/consumer products. The company is privately held, located in Victor, NY, and was founded in 2002 by David Henderson. The New Scale team has more than 100 years of combined experience with precision positioning and piezoelectric ceramic motors including their technologies, markets, applications, and customers. For more information, please visit www.newscaletech.com.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.